Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. ARDT
stocks logo

ARDT

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax
Wall Street analysts forecast ARDT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ARDT is 13.96 USD with a low forecast of 10.00 USD and a high forecast of 17.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
13 Analyst Rating
Wall Street analysts forecast ARDT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ARDT is 13.96 USD with a low forecast of 10.00 USD and a high forecast of 17.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Buy
4 Hold
1 Sell
Moderate Buy
Current: 8.870
sliders
Low
10.00
Averages
13.96
High
17.00
Current: 8.870
sliders
Low
10.00
Averages
13.96
High
17.00
JPMorgan
Neutral
downgrade
$15 -> $12
2025-11-24
Reason
JPMorgan
Price Target
$15 -> $12
2025-11-24
downgrade
Neutral
Reason
JPMorgan lowered the firm's price target on Ardent Health to $12 from $15 and keeps a Neutral rating on the shares. The firm updated the company's model post the Q3 report.
Mizuho
Outperform
to
NULL
downgrade
$20 -> $13
2025-11-18
Reason
Mizuho
Price Target
$20 -> $13
2025-11-18
downgrade
Outperform
to
NULL
Reason
Mizuho lowered the firm's price target on Ardent Health to $13 from $20 and keeps an Outperform rating on the shares. The company reported a disappointing quarter on elevated professional fees and payer denials, but "there is a path to mitigating these costs over time," the analyst tells investors in a research note. The firm believes Ardent's demand trends appear strong and support sales growth in the near- to medium-term.
Guggenheim
Buy
downgrade
$18 -> $15
2025-11-18
Reason
Guggenheim
Price Target
$18 -> $15
2025-11-18
downgrade
Buy
Reason
Guggenheim lowered the firm's price target on Ardent Health to $15 from $18 and keeps a Buy rating on the shares. Management will have to execute on core stability and ultimately more normalized growth considerations now that the DPP-related EBITDA pops are behind them, the analyst tells investors in a post-earnings note.
UBS
AJ Rice
Buy
downgrade
$17
2025-11-17
Reason
UBS
AJ Rice
Price Target
$17
2025-11-17
downgrade
Buy
Reason
UBS analyst AJ Rice lowered the firm's price target on Ardent Health to $14.50 from $17 and keeps a Buy rating on the shares.
KeyBanc
Overweight -> Sector Weight
downgrade
2025-11-17
Reason
KeyBanc
Price Target
2025-11-17
downgrade
Overweight -> Sector Weight
Reason
KeyBanc downgraded Ardent Health to Sector Weight from Overweight without a price target following the Q3 report. The company's EBITDA baseline exiting 2025 "seems less certain" and KeyBanc's 2026 estimates are moving materially lower, the analyst tells investors in a research note. The firm cites Ardent's emerging pressures from payor denials and professional fees in radiology for the downgrade. It would like to gain confidence that these issues aren't getting worse before again recommending the shares.
Stephens
Raj Kumar
Overweight
maintain
$21 -> $17
2025-11-14
Reason
Stephens
Raj Kumar
Price Target
$21 -> $17
2025-11-14
maintain
Overweight
Reason
Stephens analyst Raj Kumar lowered the firm's price target on Ardent Health to $17 from $21 and keeps an Overweight rating on the shares. Q3 was "encouraging from a volume perspective," but overshadowing the strong demand indicators was the roughly $53M 2025 EBITDA guidance cut that was influenced roughly equally by reacceleration in professional fees growth and payer denial activity in the second half. The firm lowered its 2025-2027 adjusted EBITDA-NCI estimates following the report, the analyst noted.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Ardent Health Inc (ARDT.N) is 6.86, compared to its 5-year average forward P/E of 8.46. For a more detailed relative valuation and DCF analysis to assess Ardent Health Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average PE
8.46
Current PE
6.86
Overvalued PE
10.33
Undervalued PE
6.60

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
7.62
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
8.86
Undervalued EV/EBITDA
6.38

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.34
Current PS
0.00
Overvalued PS
0.40
Undervalued PS
0.27
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

ARDT News & Events

Events Timeline

(ET)
2025-11-18
09:30:38
Ardent Health unveils $50 million stock buyback initiative
select
2025-11-13 (ET)
2025-11-13
12:00:05
Ardent Health Experiences a 33.2% Decline
select
2025-11-13
10:00:03
Ardent Health Experiences a 30.2% Decline
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
7.0
06:42 AMPRnewswire
Ardent Health Faces Investigation Over $43M Revenue Drop and $54M Liability Increase
  • Financial Transparency Issues: Ardent Health disclosed a $43 million revenue drop in its Q3 2025 earnings report due to changes in accounts receivable collectability estimates, raising significant concerns among investors regarding the company's financial transparency.
  • Increased Liability Reserves: The company also reported a $54 million increase in professional liability reserves related to claims in New Mexico, which could adversely affect future profitability and cash flow.
  • Stock Price Volatility: Following the disclosures, Ardent Health's stock price significantly declined during pre-market trading on November 13, 2025, reflecting market concerns about the company's financial health and potentially diminishing investor confidence.
  • Legal Investigation Initiated: Shareholder rights law firm Johnson Fistel is investigating whether Ardent Health and its executives violated federal securities laws, and if confirmed, such violations could severely impact the company's future operations and reputation.
[object Object]
Preview
7.0
12-04Globenewswire
Ardent Health Faces Investigation After $43M Revenue Drop Due to Accounting Change
  • Accounting Estimate Change: Ardent Health reported a $43 million revenue decrease in Q3 2025 due to a modification in the technique for estimating accounts receivable collectability, indicating potential issues with the company's financial transparency.
  • Stock Price Impact: Following this announcement, Ardent's stock price dropped, reflecting market concerns about the company's financial health, which could undermine investor confidence and future financing capabilities.
  • Legal Investigation Initiated: Holzer & Holzer, LLC is investigating whether Ardent violated federal securities laws, and if wrongdoing is found, the company may face legal liabilities and compensation claims, further exacerbating its financial pressures.
  • Investor Rights Protection: Affected investors are encouraged to contact legal counsel to discuss their rights, highlighting the growing concern and demand for investor protection in light of the company's financial issues being exposed.
[object Object]
Preview
7.0
12-03PRnewswire
Ardent Health Faces Investigation Over $97M Accounting Adjustments Following Q3 2025 Disclosures
  • Accounting Adjustments Impact: Ardent Health disclosed significant accounting adjustments totaling $97 million in its Q3 2025 report, resulting in a stock price drop of over 33%, indicating a severe deterioration in the company's financial health.
  • Revenue Reduction Issues: The $43 million revenue reduction raises questions about the effectiveness of internal controls, with the investigation focusing on whether management was aware of and failed to disclose these issues, potentially undermining investor confidence.
  • Increased Liability Reserves: The company also increased its liability reserves by $54 million, with the investigation examining whether these reserves were timely and compliant with GAAP and SEC regulations, which could impact future financial reporting and compliance.
  • Future Financial Outlook: The undisclosed accounting issues have led to a significant cut in 2025 adjusted EBITDA guidance, which may decrease investor confidence in the company's future profitability and subsequently affect stock performance.
Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Ardent Health Inc (ARDT) stock price today?

The current price of ARDT is 8.87 USD — it has decreased -0.67 % in the last trading day.

arrow icon

What is Ardent Health Inc (ARDT)'s business?

Ardent Health, Inc., formerly Ardent Health Partners, Inc., is a provider of healthcare in mid-sized urban communities across the United States. Through its subsidiaries, the Company delivers care through a system of 30 acute care hospitals and approximately 280 sites of care with over 1,800 affiliated providers across six states. It provides both general and specialty services, including internal medicine, general surgery, cardiology, oncology, orthopedics, women’s services, neurology, urology, and emergency services, within inpatient and ambulatory care settings. In addition to its 30 acute care hospitals, it operates a network of ambulatory facilities and telehealth services, including primary care and specialty care clinics, ambulatory surgery centers (ASCs), urgent care centers, free-standing emergency departments, and diagnostic imaging centers. It operates a consumer-centric healthcare platform focused on creating relationships with its patients across multiple care settings.

arrow icon

What is the price predicton of ARDT Stock?

Wall Street analysts forecast ARDT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ARDT is 13.96 USD with a low forecast of 10.00 USD and a high forecast of 17.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Ardent Health Inc (ARDT)'s revenue for the last quarter?

Ardent Health Inc revenue for the last quarter amounts to 1.58B USD, increased 8.75 % YoY.

arrow icon

What is Ardent Health Inc (ARDT)'s earnings per share (EPS) for the last quarter?

Ardent Health Inc. EPS for the last quarter amounts to -0.17 USD, decreased -189.47 % YoY.

arrow icon

What changes have occurred in the market's expectations for Ardent Health Inc (ARDT)'s fundamentals?

The market is revising Upward the revenue expectations for Ardent Health, Inc. (ARDT) for FY2025, with the revenue forecasts being adjusted by 0.22% over the past three months. During the same period, the stock price has changed by -32.60%.
arrow icon

How many employees does Ardent Health Inc (ARDT). have?

Ardent Health Inc (ARDT) has 19200 emplpoyees as of December 05 2025.

arrow icon

What is Ardent Health Inc (ARDT) market cap?

Today ARDT has the market capitalization of 1.27B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free